Pain Management Headlines

DA is taking new steps to help assess opioid drugs with abuse-deterrent properties

Statement from FDA Commissioner Scott Gottlieb, M.D. – FDA is taking new steps to help assess opioid drugs with abuse-deterrent properties

Centrexion Therapeutics Announces New 6-Month Data Demonstrating Significant and Durable Pain Relief with CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain

Centrexion Therapeutics Announces New 6-Month Data Demonstrating Significant and Durable Pain Relief with CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain

Flexion Therapeutics to Present Data on Zilretta™ (FX006) at the American Diabetes Association's 77th Scientific Sessions

Flexion Therapeutics to Present Data on Zilretta™ (FX006) at the American Diabetes Association's 77th Scientific Sessions

FDA requests removal of Opana ER for risks related to abuse

FDA requests removal of Opana ER for risks related to abuse

Grünenthal enters agreement with AstraZeneca to acquire global rights to migraine treatment Zomig® (Zolmitriptan)

Grünenthal enters agreement with AstraZeneca to acquire global rights to migraine treatment Zomig® (Zolmitriptan)

Egalet Partners with Ascend Therapeutics® U.S., LLC to Co-Promote SPRIX® Nasal Spray

Egalet Partners with Ascend Therapeutics® U.S., LLC to Co-Promote SPRIX® Nasal Spray

Califf, FDA top officials call for sweeping review of agency opioids policies

Califf, FDA top officials call for sweeping review of agency opioids policies

Geriatric Pain - 46TH Annual Winter Refresher Course for Family Medicine

Geriatric Pain - 46TH Annual Winter Refresher Course for Family Medicine

Practical Neurology - Chronic Migraine: Impact on Family Reminds of Need to Manage Effectively

Practical Neurology - Chronic Migraine: Impact on Family Reminds of Need to Manage Effectively

Opioid Prescribing for Chronic Pain — Achieving the Right Balance through Education

Opioid Prescribing for Chronic Pain — Achieving the Right Balance through Education

FDA approves Onzetra Xsail for acute treatment of migraine

FDA approves Onzetra Xsail for acute treatment of migraine

Study: New drug could be safer, non-addictive alternative to morphine

Study: New drug could be safer, non-addictive alternative to morphine

Recro Pharma Initiates Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain

Recro Pharma Initiates Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain

Study: Americans ignore dosage labels, consume too many pain meds

Study: Americans ignore dosage labels, consume too many pain meds

Migraines Worsen As Women Approach Menopause

Migraines Worsen As Women Approach Menopause

Trevena, Inc. Announces Initiation of Oliceridine Phase 3 Clinical Program with Multi-Procedure Safety and Tolerability Study

Trevena, Inc. Announces Initiation of Oliceridine Phase 3 Clinical Program with Multi-Procedure Safety and Tolerability Study